Chief Executive Officer
Risto Lammintausta has over 30 years of drug development experience in different positions of R&D management, from Farmos Group, Orion Pharma, Hormos Medical and QuatRx. During his career, five new compound discoveries have been launched to global markets, including Ospemifene. In 2013, he co-founded and became CEO of Forendo Pharma. Risto has served as a board member for several biopharma companies and has had positions of trust in associations for Finnish Bioindustry, Chemical Industry and Pharma Industry.